Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.
about
Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximabPatients with systemic lupus erythematosus and haematological malignancy at a tertiary care centre: timing, histopathology and therapyThe European Hematology Association Roadmap for European Hematology Research: a consensus documentPretransplant FDG-PET in aggressive non-Hodgkin lymphoma: systematic review and meta-analysis.Mature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications.Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry.Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base.Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma.Outcome of Elderly Patients with Diffuse Large B-cell Lymphoma Treated with R-CHOP: Results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.Prognostic significance of neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma: A meta-analysis.A combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment.Assessment of the circulating cell-free DNA marker association with diagnosis and prognostic prediction in patients with lymphoma: a single-center experience.R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma.R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absentMYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCLMy treatment approach to patients with diffuse large B-cell lymphoma.Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study.KMWin--a convenient tool for graphical presentation of results from Kaplan-Meier survival time analysisA new prognostic score for AIDS-related lymphomas in the rituximab-era.Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.Utilization of the Eμ-Myc mouse to model heterogeneity of therapeutic response.Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.Modelling chemotherapy effects on granulopoiesis.Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment.Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models.FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma.The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphomaCHOP-like-14 compared to CHOP-like-21 for patients with aggressive lymphoma--a meta-analysis of randomized controlled trials.Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathyConstitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphomaAIDS-Related Non-Hodgkin's Lymphoma in the Era of Highly Active Antiretroviral TherapyClinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvementSynergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1Localized primary gastrointestinal diffuse large B cell lymphoma received a surgical approach: an analysis of prognostic factors and comparison of staging systems in 101 patients from a single institution.
P2860
Q24597424-12462CFE-37A1-466D-AF30-026D66828D46Q28256567-0ED353C6-63FE-40D9-A9E2-6211552239CAQ28651110-4DAE63C6-1112-4676-AE8E-DC15044CE475Q28830861-7E0C1D08-1AB2-434D-861B-8D688F1A0ECBQ30240084-9BE4FBC6-89B0-423F-B620-CC5A1637BAB0Q30240133-9430F9C0-AEC6-41C8-8DBF-33F492E02F89Q30275206-5DBB3BD0-82F3-4614-B74F-F847204AF451Q30653421-025E6F5F-C52E-403F-B85B-2DBD4AC1EA5AQ30967984-14DE8026-8C7F-4E2E-AAE4-4FD342DF19F8Q33435420-5D972119-140D-43FD-85C9-6ED2B38FEEC5Q33440896-66D91820-BF95-4330-ABE3-F9D2BB6B7093Q33591789-E88AA45A-CD55-4783-8D6E-27109BA07730Q33602512-FA6494A1-27C0-402F-A437-351A9C1C6F7FQ33712928-987D8F6C-242E-44DC-B761-C2298D7819C1Q33841321-00F711BE-CC01-4DD3-AAB6-F42A9C9D5654Q33875883-4C6957BA-54C5-4EBB-8D93-17CB1974DC4CQ33934326-75AFFC1C-D24F-49B0-B103-FE61DEDB20D1Q33945770-981E9120-12DE-4772-9037-D5CABB373656Q34000188-0ECFA386-0EF7-4FB1-873A-2D1BCB1A2825Q34100855-89757C82-25A5-421F-B538-B4422D4F598EQ34251964-12194A27-74F4-4BA4-ABA6-8C61DAD0BE78Q34308997-0A75A325-77E7-465D-9B9E-2DCE40FF86D1Q34314040-7922CF90-282D-47D7-BBCE-285D4BC8944BQ34463597-066F0821-61C2-4D93-9D73-EDF1D5CFBC3CQ34543066-F73A3069-BD4A-45FB-83CF-C278EFF173BFQ34646755-9EA08FAD-6CE4-4ADB-B6A6-3CA50A06ECF7Q34882773-F3D901A1-B557-4742-B8A3-9476ACFF32CBQ34996295-BC30CBF5-B235-4B9E-8E8F-500110E03B69Q35143471-ACFBA419-C506-4551-9FA0-999753609745Q35153794-0115DBAE-8D0E-41EF-8EE4-B4C2CBF8CA25Q35402899-4FCEB040-E9F1-47A4-8E5F-59642BEE9B9BQ35556842-2AAD6F2C-115A-4F35-BB6E-D6438F210B3FQ35606714-4CA5D5AD-D429-4B88-AD17-F37CF9FCEC3EQ35638549-71508B10-A1D6-456A-B69D-79FEC4DD3830Q35673260-71432307-C1E4-48B5-B7AB-4663E930F6F8Q35740025-2A77FDF2-12F7-40B0-83E6-6D1ABEA9645FQ35779619-B4B151E1-D48E-42E5-BC8E-ADA1A7DAAA15Q35871945-0239B042-6643-447B-BB20-70A6FFDB46BFQ35920657-DB0B6A15-5725-42D3-84DA-EF42FD54381DQ35954113-CB0E68E0-449F-42E3-8530-A322081D2135
P2860
Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Standard International prognos ...... lymphoma in the rituximab era.
@en
Standard International prognos ...... lymphoma in the rituximab era.
@nl
type
label
Standard International prognos ...... lymphoma in the rituximab era.
@en
Standard International prognos ...... lymphoma in the rituximab era.
@nl
prefLabel
Standard International prognos ...... lymphoma in the rituximab era.
@en
Standard International prognos ...... lymphoma in the rituximab era.
@nl
P2093
P356
P1476
Standard International prognos ...... lymphoma in the rituximab era.
@en
P2093
Bertram Glass
Dirk Hasenclever
Evelyn Kuhnt
Marita Ziepert
Markus Loeffler
Norbert Schmitz
P304
P356
10.1200/JCO.2009.26.2493
P407
P577
2010-04-12T00:00:00Z